Company Earnings Update 3 minutesRegister for Free AccessCVS (CVS) 3Q17 Results: Beats on EPS, in Line on Revenues; Raises/Narrows FY17 EPS Guidance Coresight Research November 7, 2017 Executive Summary CVS Health reported 3Q17 adjusted EPS of $1.50, down 9.9% year over year and beating the $1.48 consensus estimate. Revenues were $46.2 billion, up 3.5% year over year and in line with the consensus estimate. Pharmacy Services was the faster-growing segment, with revenues up 8.1% year over year, to $32.9 billion. Revenues in the Retail/LTC (Long-Term Care) segment declined by 2.7%, to $19.6 billion. The company narrowed and raised the midpoint of its FY17 adjusted EPS guidance to $5.87–$5.91 from $5.83–$5.93 previously. Please Login to read the full report. Not a member? Register for a free user account. This document was generated for Other research you may be interested in: Coresight Bites: How US Consumers Spent in 2022—Pandemic-Fueled Imbalance Is Yet To Be CorrectedJuly 2023 Leading Indicators of US Retail Sales: Projecting Low-Single-Digit Growth Amid Marginal Disposable Income RiseWeinswig’s Weekly: US Retail Bankruptcies Jump 10X in 2023June 2023 US Retail Sales: Higher Wages and Slower Inflation Drive Moderate Retail Sales Growth
